On April 23, 2026 SkylineDx, an innovative company specializing in molecular diagnostics for dermatology, reported the latest research on the company’s precision molecular diagnostics advances, including a new gene expression signature. The gene expression signature, SCC Outcome Risk Estimation Gene Expression Profile (SCCore GEP), can predict metastatic events in CSCC, outperforming the existing staging system. The signature will be highlighted in an oral presentation at the 22nd European Association of Dermato-Oncology (EADO) Congress, taking place April 23-25, in Prague and online.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral presentation: "A gene expression signature enables metastatic risk stratification of low-risk cutaneous squamous cell carcinoma patients."
CSCC is the second most common form of skin cancer, with 1.8 million cases per year in the U.S.¹˒² and 56,000 deaths per year, globally³˒⁴.Incidence has also increased by 200% over the past three decades⁵.
Over one-third of metastases occur in CSCC patients traditionally classified as "low risk" (T1, T2a)⁶. Despite constituting 90% of the CSCC population, current staging systems fail to stratify these patients correctly. Professor Marlies Wakkee, Department of Dermatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands, presents findings on a novel gene expression signature for CSCC.
"This molecular profiling approach enables personalized risk stratification so clinicians can intensify diagnostic work-ups and monitoring for true high-risk patients while avoiding over-treatment of low-risk patients," said Prof. Wakkee. "By implementing risk-informed patient management strategies, metastatic events can be detected and treated early or may even be prevented."
"This marks our first oral presentation at a conference on our CSCC signature, representing our progress toward more accurate risk stratification for this high incidence disease," said Dharminder Chahal, SkylineDx CEO. "These findings underscore the value of integrating molecular diagnostics into standard clinical practice, demonstrating how precision tools can enhance patient care and guide treatment decisions."
(Press release, SkylineDx, APR 23, 2026, View Source [SID1234664732])